For years, countless veterans have cycled through pills, waiting rooms, and sleepless nights, told to “manage” pain that never really leaves. With one executive order, Donald Trump yanked a taboo topic into the center of federal policy: psychedelics as medicine. By directing the FDA to accelerate review of certain breakthrough-designated compounds, he opened a controversial shortcut through a system famous for moving slowly, even when lives hang in the balance.
Supporters see a rare moment of courage, a chance to turn cutting‑edge science into real relief for people who have sacrificed everything. Critics warn that political pressure and public desperation could outpace caution, and that vulnerable patients might become test cases in a national experiment. Between those extremes stand the veterans themselves, weighing risk against another year of suffering, and wondering if this unexpected order might finally change everything.
